- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Pasithea Therapeutics Corp(KTTA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KTTA
11/13/2026: KTTA (1-star) is currently NOT-A-BUY. Pass it for now.
Pasithea Therapeutics Corp is a clinical-stage biotechnology company focused on developing targeted small-molecule treatments for RASopathies, MAPK pathway-driven tumors, and CNS disorders. The company's primary strength lies in its lead candidate, PAS-004, a next-generation macrocyclic MEK inhibitor designed to overcome resistance issues associated with older therapies. Its core investment opportunity centers on clinical trial progress and potential orphan drug positioning, though it faces substantial execution, regulatory, and dilution risks typical of pre-revenue biotechnology firms. The stock is best suited for high-risk growth investors comfortable with extreme volatility and binary clinical milestones. Investors should closely monitor upcoming clinical data readouts, cash burn metrics, and regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers high-risk, high-reward exposure to clinical-stage drug development, but lacks commercial revenue growth metrics. |
| Momentum investor | Strong fit while signal remains positive | Micro-cap clinical stocks can experience sharp, catalyst-driven price spikes around positive trial data updates. |
| Value investor | Weak fit | Traditional fundamental valuation metrics such as P/E ratios and earnings are absent due to ongoing net losses. |
| Dividend investor | Weak fit | The company pays no dividends and retains all capital for research operations. |
| Low-risk investor | Weak fit | High clinical uncertainty, equity volatility, and pre-revenue financial profiles expose investors to total capital loss risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap biotech stocks frequently experience extreme price swings triggered by trial updates or market sentiment. |
| Valuation risk | High | Valuations are entirely speculative, depending on clinical milestones rather than tangible earnings or cash flows. |
| Competition risk (biopharmaceutical oncology competition) | High | The company competes with heavily funded pharmaceutical firms developing alternative kinase inhibitors. |
| Business quality | Medium | While scientific leadership is strong, the enterprise remains an early-stage research outfit without approved commercial products. |
| Dividend income | Low / none | No dividend distributions are provided or anticipated in the near term. |
| Execution risk | High | Success depends on error-free clinical execution, patient recruitment, and navigating complex regulatory pathways. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.44M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1.2M shares | Beta 0.44 | 52 Weeks Range 0.28 - 2.06 | Updated Date 11/15/2026 |
52 Weeks Range 0.28 - 2.06 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -56.55% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Therapeutics Development | Future commercialization and licensing of targeted oncology and CNS drug candidates, currently yielding zero revenue. | The company does not sell commercial products yet and operates entirely on equity financing while advancing drugs through clinical trials. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -28.31M | Price to Sales(TTM) 42.15 |
Enterprise Value -28.31M | Price to Sales(TTM) 42.15 | ||
Enterprise Value to Revenue 277.44 | Enterprise Value to EBITDA 2.9 | Shares Outstanding 33.41M | Shares Floating 26.00M |
Shares Outstanding 33.41M | Shares Floating 26.00M | ||
Percent Insiders 1.11 | Percent Institutions 59.9 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

